Industrial, Manufacturing & Heavy Industry Market News

Global biosimulation market set to exceed US$ 1,750 mn in 2022

Industrial Market Research

The Global Biosimulation Market is set to be worth about US$ 1,750 Mn in the Year 2022.

In the process of biosimulation, the computer aided mathematical models are used to simulate the biological processes. Biosimulation is an important part of systems biology and helps in the discovery and development of new drugs, in the area of drug metabolism and in the modeling of biomedical systems that are complex.

There is a growing demand for reduction in the cost of discovery of new drugs and the risk of failure at a later stage in the development of new drugs is too high. In order to counter such problems, biosimulation is used as a predictive tool and it helps in the prediction of the future outcomes of the drug development by simulation of the biological processes involved.

This is the main factor supporting the growth of the global biosimulation market. However, high costs associated with the R&D related to biosimulation and a lack of qualified workforce are the main restraints hampering the growth of this market.

Access full report now @ www.persistencemarketresearch.com/checkout/3726

The global biosimulation market is slated to touch a value of about US$ 1,750 Mn in the year 2022 and grow at a robust CAGR during the assessment period.  

Access Report  @ www.persistencemarketresearch.com/…iple-chapter/3726

4 Forecast Highlights on Global Biosimulation Market

As per the forecast of Persistence Market Research, the services product type segment is slated to touch a value of nearly US$ 700 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022.

The services product type segment is estimated to account for more than one-third of the revenue share of the product segment by the year 2017 and is forecasted to gain market share by 2022 over 2017.

As per the forecast of Persistence Market Research, the pharmaceutical and biotech companies segment will reach a value of about US$ 350 Mn in the year 2017. This represents a robust CAGR growth during the forecast period.

The pharmaceutical and biotech companies segment is forecasted to account for more than one-third of the total revenue share of the end user segment by the end of the year 2017 and is expected to lose in market share by 2022 as compared with the year 2017.

Access Sample of Report @  www.persistencemarketresearch.com/samples/3726

As per the forecast of Persistence Market Research, the drug development segment is slated to reach a value of nearly US$ 1,000 Mn in 2022. The drug development segment is expected to gain market share by the end of the year 2022.

The largest share is contributed by the North America region in the drug development segment.   

Persistence Market Research forecasts the U.S. biosimulation market to exhibit a compound annual growth rate (CAGR) of more than 13% from 2017 to 2022.

Access Report with Table of Contents @  www.persistencemarketresearch.com/…lation-market/toc
 
The report has also included the profiles of some of the leading companies in the biosimulation market like Dassault Systemes SE, Acceryls Inc., Schrodinger, Inc., Leadscope Inc., Certara, L.P., Entelos, Inc., Advanced Chemistry Development, Inc., Evidera, Inc., Simulations Plus, Inc. and Genedata AG.

More information @ www.prnewswire.com/news-releases/b…ch-649412963.html

News From

Persistence Market ResearchPersistence Market Research
Category: Market Research Publishers and RetailersCompany about: Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intel ...
This email address is being protected from spambots. You need JavaScript enabled to view it.